Schafer Edward T 4
4 · Cellular Biomedicine Group, Inc. · Filed Feb 19, 2021
Insider Transaction Report
Form 4
Schafer Edward T
Director
Transactions
- Disposition to Issuer
Non-Qualified Stock Option
2021-02-19−5,044→ 0 totalExercise: $14.93From: 2020-04-24Exp: 2029-10-12→ Common Stock (5,044 underlying) - Disposition to Issuer
Non-Qualified Stock Option
2021-02-19−4,983→ 0 totalExercise: $14.68From: 2021-04-23Exp: 2030-04-25→ Common Stock (4,983 underlying)
Footnotes (3)
- [F1]Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 11, 2020, by and among Cellular Biomedicine Group, Inc. (the "Company"), CBMG Holdings ("Parent") and CBMG Merger Sub Inc. ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving the Merger as a wholly-owned subsidiary of Parent (the "Merger"). The Merger became effective on February 19, 2021 (the "Closing Date"). Pursuant to the Merger Agreement, at the effective time of the Merger, each stock option was cancelled and exchanged for the right to receive an amount in cash equal to (A) the total number of shares of common stock subject to such stock option multiplied by (B) the excess, if any, of the per share merger consideration of $19.75 over the exercise price of the stock option.
- [F2]The exercise price of this option to purchase shares of common stock was previously reported erroneously as $14.65 in the Reporting Person's Form 4 filed on April 28, 2020.
- [F3]In connection with the Merger, unvested options were accelerated and vested in full at the effective time of the Merger.